Verrica Pharmaceuticals Inc (VRCA)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Verrica Pharmaceuticals Inc chart...

About the Company

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.

CEO

Ted White

Exchange

NASDAQ

Website

http://www.verrica.com/

$5M

Total Revenue

31

Employees

$240M

Market Capitalization

-4.64

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $VRCA News

Verrica Pharma gains as FDA lists Ycanth in Orange Book

on MSN ago, source:

Verrica Pharmaceuticals (VRCA) receives FDA's NCE status for Ycanth, as FDA lists the antiviral in its Orange Book with five ...

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

2d ago, source:

NCE status provides a minimum of five years of regulatory exclusivityThe Company’s U.S. patents and pending patent applications related to ...

Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts

2d ago, source:

Verrica Pharmaceuticals Inc. (VRCA) announced the company's lead product, YCANTH, has received New Chemical Entity Status and a ...

Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript

28d ago, source: Seeking Alpha

Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Fourth Quarter and Year End 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is ...

When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?

27d ago, source: Yahoo Finance

We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA) business as it appears the company may be on the cusp of a considerable accomplishment. Verrica ...

Verrica Pharmaceuticals Inc VRCA

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

28d ago, source: Nasdaq

WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing ...

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

2d ago, source: Yahoo Finance

WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics ...

Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts

2d ago, source: Nasdaq

(RTTNews) - Verrica Pharmaceuticals Inc. (VRCA) announced the company's lead product, YCANTH, has received New Chemical Entity Status and a listing in the Orange Book from the FDA, providing a ...

Verrica Pharmaceuticals Inc VRCA

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

28d ago, source: Stockhouse

WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin ...

Verrica Pharmaceuticals Announces that YCANTH(TM) Receives New Chemical Entity Status and Orange Book Listing from the FDA

2d ago, source: Stockhouse

March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...